Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
SPRB
vs
S&P 500
SPRB
S&P 500
Over the past 12 months, SPRB has underperformed S&P 500, delivering a return of -76% compared to S&P 500's +16% growth.
Stocks Performance
SPRB vs S&P 500
Performance Gap
SPRB vs S&P 500
Performance By Year
SPRB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Spruce Biosciences, Inc
Glance View
Spruce Biosciences is a development-stage biotechnology company that works on medicines for rare endocrine disorders, especially conditions tied to abnormal hormone production. Its main drug candidate has been tildacerfont, an oral medicine designed to treat congenital adrenal hyperplasia, a lifelong genetic disease that can cause the body to make too many stress hormones. The company does not sell a broad portfolio of medicines. Instead, it spends its money on research, clinical trials, and regulatory work to try to turn one or a few drug candidates into approved treatments. If those drugs succeed, Spruce would make money through product sales, and possibly through partnerships or licensing deals with larger drug companies. What makes Spruce different is its narrow focus on a small group of hard-to-treat hormone disorders rather than common diseases. That puts it in the role of a specialist drug developer: it is trying to solve a very specific medical problem where patients often have limited treatment options and where success depends on strong clinical data and approval from health regulators.